Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19.

ABSTRACT:

Purpose

Limited data are available on venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe hypoxemic respiratory failure from coronavirus disease 2019 (COVID-19).

Methods

We examined the clinical features and outcomes of 190 patients treated with ECMO within 14 days of ICU admission, using data from a multicenter cohort study of 5122 critically ill adults with COVID-19 admitted to 68 hospitals across the United States. To estimate the effect of ECMO on mortality, we emulated a target trial of ECMO receipt versus no ECMO receipt within 7 days of ICU admission among mechanically ventilated patients with severe hypoxemia (PaO₂/FiO₂ < 100). Patients were followed until hospital discharge, death, or a minimum of 60 days. We adjusted

SUBMITTER: Shaefi S 

PROVIDER: S-EPMC7851810 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature